-

12:11:56 AM

ASLN Stock News

ASLN - ASLAN Pharmaceuticals Ltd

05/25/22 7:00 AM

OTC, Nasdaq : ATBPF, ASLN

management

Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs

Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. Dr. Wallace is also taking the opportunity to return to his vocation as a...

RHEA-AI

neutral

05/20/22 7:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting

RHEA-AI

neutral

05/18/22 7:00 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a

RHEA-AI

neutral

05/10/22 7:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting new data and

RHEA-AI

neutral

04/27/22 7:00 AM

Nasdaq : ASLN

earnings

ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) progressing, multiple sites enrolling; topline data expected in the first half of 2023 Alex Kaoukhov, MD, appointed as Chief Medical Officer, adding global pharma leadership experience ahead of advancing eblasakimab

RHEA-AI

neutral

04/12/22 8:00 AM

Nasdaq : ASLN

management

Oak Hill Bio Announces Formation of Board of Directors

Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced the formation of the Company’ s Board of Directors, which brings together a team of experienced leaders with collective expertise...

RHEA-AI

neutral

04/06/22 7:00 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at

RHEA-AI

neutral

04/01/22 5:00 PM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC

RHEA-AI

neutral

03/28/22 7:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from the

RHEA-AI

neutral

03/25/22 7:00 AM

Nasdaq : ASLN

earnings

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023 New CMO appointed, adding senior global pharma experience to the leadership team Company maintains strong operating position with US$90.2 million in cash

RHEA-AI

neutral

ASLN Data

IndustryPharmaceutical Preparation Manufacturing
Websiteaslanpharma.com
CeoCarl Firth
Security nameASLAN Pharmaceuticals Ltd - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2021
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
State12 03 Ue Square
City83 Clemenceau Avenue
Zip239920
CountrySingapore
Phone6562224235

About ASLAN Pharmaceuticals Ltd

ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.